Cardiovascular complications are the principal cause of death in type 2 diabetes. The importance of glycaemic control in preventing cardiovascular complications has been demonstrated. However, some oral antidiabetic agents and especially some sulphonylureas (SU) have been accused of having a deleterious effect on cardiovascular risk. A retrospective analysis of the administrative database of Saskatchewan Health for 5,795 subjects, identified by their first-ever dispensation for an oral antidiabetic agent, suggests that a higher exposure to SUs was associated with increased mortality. Nevertheless, the effects of SUs on cardiac ATP-sensitive potassium channels in experimental studies vary between agents and studies, so that the clinical relevance of this phenomenon is unclear. Moreover, 11 years of follow-up of patients randomised to glibenclamide or chlorpropamide in the United Kingdom Prospective Diabetes Study demonstrated no adverse effects on a range of cardiovascular end points. Despite SU structural differences and differences in binding to cardiac SU receptors, the clinical evidence base does not support the selection of one sulphonylurea over another on the basis of ischaemic preconditioning, possibly because ischaemic preconditioning may be blunted or absent in diabetes. The main objective remains the prevention or delay of diabetic complications through improvement of glycaemic control together with other cardiovascular risk factors.
Mensah GA, Mokdad AH, Ford E. et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin2004;22:485-504.
2.
De Backer G. , Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) . Eur J Cardiovasc Prev Rehabil2003;10(suppl 1):S1-S78.
3.
Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001;285:2486-97.
4.
Clinical Guidelines Task Force, International Diabetes Federation.2005Global Guideline for Type 2 Diabetes . Available at www.idf.org
5.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
6.
Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977-86.
7.
Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med2005;353:2643-53.
8.
Goldner MG, Knatterud GL, Prout TEEffects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA1971;218:1400-10.
9.
Selzer HSA summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes1972 ;21:976-9.
10.
Feinglos MN , Bethel MATherapy of type 2 diabetes, cardiovascular death and the UGDP. Am Heart J1999;138:S346-S52.
11.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
12.
Malmberg K.Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ1997;314:1512-15.
13.
Malmberg K. , Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J2005;26:650-61.
14.
Hirsch IBWere we wrong about insulin and acute myocardial infarction?DOC News2004;1:4-5.
15.
Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JADose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ2006;174: 169-74.
16.
Granberry MC , Fonseca VACardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs2005;5:201-09.
17.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65.
18.
Charbonnel B., Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.; PROactive Study Group.The prospective pioglitazone clinical trial in macrovascular events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care2004;27:1647-53.
19.
Dormandy JA , Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005;366:1279-89.
20.
Rendell M.The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs2004;64:1339-58.
21.
Guillausseau PJHyperglycémie et hypoglycémiants : risques vasculaires. Réal Cardiol2005;207:39-42.
22.
Bailey CJOral antidiabetic drugs in Encyclopedic Reference of Molecular Pharmacology 2004. Offerman S, Rosenthal W (eds). Springer-Verlag, Heidelberg2004;688-95.
23.
Ashcroft FM , Gribble FMATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia1999;42:903-19.secretion:
24.
Gribble FM, Ashcroft FMDifferential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide. Diabetologia1999;42:845-8.
25.
Downey JMAn explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning. Cardiovasc Res1993;27:1565.
26.
Gross GJAuchampach JABlockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res1992;70:223-33.
27.
Ishihara M. , Inoue I., Kawagoe T. et al. Diabetes mellitus prevents ischaemic preconditioning in patients with a first acute anterior wall myocardial infarction . J Am Coll Cardiol2001;38:1007-11.
28.
Ghosh S., Standen NB, Galinianes M.Failure to precondition pathological human myocardium. J Am Coll Cardiol2001;37:711-18.
29.
Lee TM, Chou TFImpairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab2003;88:531-7.
30.
Gaines KL, Hamilton S., Boyd AE 3rd.Characterisation of the sulfonylurea receptor on beta cell membranes. J Biol Chem1988;263:2589-92.
31.
Riveline JP , Danchin N., Ledru F., Varroud-Vial M., Charpentier G.Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab2003;29:207-22.
32.
Samaha FF, Heineman FW, Ince C., Fleming J., Balaban RSATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol1992;262:C1220-7.
33.
Cyrys S., Daut J.The sensitivity of coronary vascular tone to glibenclamide: a study on the isolated perfused guinea pig heart. Cardiovasc Res1994;28:888-93.
34.
Munch-Ellingsen J., Bugge E., Ytrehus K.Blockade of the KATP-channel by glibenclamide aggravates ischaemic injury, and counteracts ischaemic preconditioning. Basic Res Cardiol1996;91:382-8.
35.
Mei DA, Gross GJEvidence for the involvement of the ATP-sensitive potassium channel in a novel model of hypoxic preconditioning in dogs. Cardiovasc Res1995;30:222-30.
36.
Qian YZ, Levasseur JE, Yoshida K., Kukreja RCKATP channels in rat heart: blockade of ischaemic and acetylcholine-mediated preconditioning by glibenclamide. Am J Physiol1996;271(1 Pt 2):H23-H28.
37.
Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J.Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels. Cardiovasc Res1993;27:623-9.
38.
Toombs CF, Moore TL, Shebuski RJLimitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res1993;27:617-22.
39.
Miura T., Goto M., Miki T., Sakamoto J., Shimamoto K., Iimura O.Glibenclamide, a blocker of ATP-sensitive potassium channels, abolishes infarct size limitation by preconditioning in rabbits anesthetized with xylazine/pentobarbital but not with pentobarbital alone. J Cardiovasc Pharmacol1995;25:531-8.
40.
Fralix TA, Steenbergen C., London RE, Murphy E.Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart. Cardiovasc Res1993;27:630-7.
41.
Jerome SN, Akimitsu T., Gute DC, Korthuis RJIschaemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol1995 ;268:H2063-7.
42.
Wilde AARole of ATP-sensitive K+ channel current in ischaemic arrhythmias. Cardiovasc Drugs Ther1993:7(suppl 3):521-6.
43.
Pogatsa G.What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents?Diabetes Res Clin Pract1996;31 (suppl):S27-S31.
44.
D'Alonzo AJ , Darbenzio RB, Hess TA, Sewter JC, Sleph PG, Grover GJEffect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res1994;28:881-7.
45.
Baczko I., Lepran I., Papp JGKATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Eur J Pharmacol1997 ;324:77-83.
46.
Vegh A., Papp JG, Szekeres L., Parratt JRAre ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning?Cardiovasc Res1993;27:638-43.
47.
Maddock HL, Siedlecka SM, Yellon DMMyocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther2004;18:113-19.
48.
Ballagi-Pordany G., Koszeghy A., Koltai MZ, Aranyi Z., Pogatsa G.Divergent cardiac effects of the first and second generation hypoglycaemic sulfonylurea compounds. Diabetes Res Clin Pract1990;8:109-14.
49.
Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DMGlimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischaemic preconditioning or diazoxide. Circulation2001;103:3111-16.
50.
Klepzig H., Kober G., Matter C. et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J1999;20:439-46.
51.
Horimoto H. , Nakai Y., Mieno S., Nomura Y., Nakahara K., Sasaki S.Oral hypoglycaemic sulfonylurea glimepiride preserves the myoprotective effects of ischaemic preconditioning. J Surg Res2002;105:181-8.
52.
El-Reyani NE , Baczko I., Lepran I., Papp JGComparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol1999;365:187-92.
53.
Scognamiglio R., Avogaro A., Vigili de Kreutzenberg S. et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes2002;51:808-12.
54.
St John Sutton M., Rendell M., Dandona P. et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with type 2 diabetes. Diabetes Care2002;25:2058-64.
55.
Lee TM, Su SF, Chou TF, Lee YT, Tsai CHLoss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation2002;105:334-40.
56.
Larsen JJ, Dela F., Madsbad S., Vibe-Petersen J., Galbo H.Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care1999;22:1647-54.
57.
Tomai F., Danesi A., Ghini AS et al. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J1999;20:196-202.
58.
Ovunc K.Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol2000;23:535-9.
59.
Ferreira BM , Moffa PJ, Falcao A. et al. The effects of glibenclamide, a K(ATP) channel blocker, on the warm-up phenomenon. Ann Noninvasive Electrocardiol2005;10:356-62.
60.
Correa SD, Schaefer S.Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol1997;79:75-8.
61.
Bogaty P., Kingma JG Jr, Robitaille NM et al. Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina: relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel . J Am Coll Cardiol1998; 32:1665-71.
62.
Lindhardt TB , Abedini S., Olesen RM, Haunso S., Gadsboll N.Effects of Pharmacological Modulation of the ATP-Sensitive Potassium Channels on the Development of Warm-Up Angina Pectoris . Cardiology2005;15: 17-21.
63.
Rana JS, Mukamal KJ, Nesto RW, Morgan JP, Muller JE, Mittleman MAEffect of diabetes mellitus and its treatment on ventricular arrhythmias complicating acute myocardial infarction. Diabet Med2005 ;22:576-82.
64.
Tentolouris N., Matsagura M., Psallas M. et al. Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin. Exp Clin Endocrinol Diabetes2005;113:298-301.
65.
Markham A., Plosker GL, Goa KLNicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs2000 ;60:955-74.
66.
Geshi E., Ishioka H., Nomizo A., Nakatani M., Katagiri T.The role of ATPsensitive potassium channels in the mechanism of ischaemic preconditioning. J Cardiovasc Pharmacol1999 ;34:446-53.
67.
Hata N., Takano M., Kunimi T., Kishida H., Takano T.Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris . Int J Clin Pharmacol Res2001;21:59-63.
68.
Danchin N., Charpentier G., Ledru F. et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry . Diabetes Metab Res Rev2005;21: 143-9.
69.
Klamann A., Sarfert P., Launhardt V., Schulte G., Schmiegel WH, Nauck MAMyocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J2000;21:220-9.
70.
Halkin A., Roth A., Jonas M., Behar S.Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis2001;12:177-84.
71.
1. Weih M., Amberger N., Wegener S., Dirnagl U., Reuter T., Einhaupl K.Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke2001;32:2029-32.
